Scarica l'app Stockscreener
4.745
3.85%
-0.185
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
Form 4 Insight Molecular Diagnostics Inc For: 6 July By Investing.com - Investing.com Nigeria
Insight Molecular Diagnostics (Nasdaq: IMDX) details director RSU tax withholding - Stock Titan
Insight Molecular (IMDX) director uses 12,100 shares to cover RSU tax withholding - Stock Titan
If You Invested $1,000 in Insight Molecular Diagnostics Inc. (IMDX) - Stock Titan
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper - GlobeNewswire
iMDx science chief hits 200 papers as transplant test work builds - Stock Titan
Insight Molecular Diagnostics Inc. Actuals & Estimates (NASDAQ:IMDX) - TradingView
Insight Molecular Diagnostics Inc. Actuals & Estimates (BOATS:IMDX) - TradingView
IMDX Forecast — Price Target — Prediction for 2027 - TradingView
IMDX Q1 2026 Earnings: Narrower-than-expected loss drives stock surgeTrough Earnings Signal - dars.gov.et
Insight Molecular Diagnostics and ASTS Award Grant for Health Economics Study of In-House vs. Send-Out dd-cfDNA Testing in Kidney Transplantation - Quiver Quantitative
iMDx and ASTS fund $100,000 study on kidney transplant testing costs - Stock Titan
Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
iMDx and the American Society of Transplant Surgeons - GlobeNewswire
Insight Molecular Diagnostics Ord Shs (IMDX) Institutional Confidence - TradingKey
IMDX SEC FilingsInsight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insight Molecular Diagnostics Validates GraftAssure Assay Superiority - HarianBasis.co
Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment - Insider Monkey
12 High-Growth Micro-Cap Stocks to Buy Now - Insider Monkey
Insight Molecular Diagnostics Ord Shs (IMDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insight Molecular Diagnostics (NASDAQ: IMDX) shareholders back plan share increase - Stock Titan
Insight Molecular Diagnostics Inc. Announces Favorable Head-To-Head Data On Imdx's Graftassure With Competing NGS Assay Published In Clinical Chemistry - marketscreener.com
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry - The Manila Times
New lab test rivals DNA sequencing to monitor kidney transplants - Stock Titan
[Form 4] Insight Molecular Diagnostics Inc. Insider Trading Activity - Stock Titan
Director Arno Andrew of Insight Molecular (IMDX) receives 32,331-share stock grant - Stock Titan
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) Stock Price, News & Analysis - Kalkine
IMDX Q1 2026 Earnings: Narrowing Losses with 55% EPS Surprise Amid Revenue DisclosuresBuyback Announcement Report - newsline.com
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation - The Manila Times
Insight Molecular Diagnostics Inc. Announces Publication of GraftAssure CM-Score Demonstrating Superior Performance in Transplant Rejection Monitoring - Quiver Quantitative
IMDX GraftAssure Assay Sets New Standard in Screening - GlobeNewswire
Study: New kidney transplant model doubles reliability of positive results - Stock Titan
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress - The Manila Times
IMDX Q1 2026 Earnings: EPS Beat Lifts Sentiment Despite No RevenueForward EPS Estimate - newsline.com
Insight Molecular Diagnostics Inc Highlights Graftassure Technology and Announces Grant Winners At American Transplant Congress - marketscreener.com
iMDx to Showcase GraftAssure Technology at American Transplant Congress and Announce Research Grant Winners - Quiver Quantitative
In-house transplant rejection test heads to key Boston conference - Stock Titan
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Insight Molecular Diagnostics (IMDX) Plunges 20% to Multi-Week Low as Selling Pressure IntensifiesDividend ETF - dars.gov.et
IMDX Q1 2026 Earnings: Strong EPS Beat Driven by Cost Discipline and Operational EfficiencyEarnings Decline Risk - newsline.com
IMDX - Finviz
IMDX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Revenue ChallengesFiscal Year Earnings - dars.gov.et
IMDX Q1 2026 Earnings: EPS beats estimates by 55% despite revenue absenceFiscal Year Earnings - newsline.com
Insight Molecular Diagnostics (IMDX) Rallies 5.75% as Bullish Momentum Builds Near Key ResistanceSynthetic Short - newsline.com
Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings: EPS Surprises to the Upside During Pre‑Revenue Phase - The Legal Advocate
Earnings call transcript: Insight Molecular Diagnostics’ Q1 2026 performance and strategic outlook - Investing.com Australia
Insight Molecular Diagnostics Balances Progress and Cash Burn - TipRanks
Insight Molecular Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IMDX) 2026-05-17 - Seeking Alpha
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission - Yahoo Finance
BTIG reiterates Neutral on Insight Molecular stock amid FDA review By Investing.com - Investing.com Nigeria
BTIG reiterates Neutral on Insight Molecular stock amid FDA review - Investing.com India
Insight Molecular Q1 2026 Earnings Call Transcript - Sahm
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):